Refine by
Therapeutic Neutralizing Antibodies Articles & Analysis
49 news found
Creative BioMart, a biotechnology company specializing in cell line development and protein production, has recently upgraded its GMP stable cell line development platform. This platform provides biopharmaceutical companies with a structured and regulatory-compliant approach to develop stable cell lines for therapeutic proteins, monoclonal antibodies, and other biologics. The cell line ...
Creative BioMart, a biotechnology company focused on protein-related research solutions, has recently upgraded its epitope mapping service to better support researchers in therapeutic antibody development, vaccine design, and immunogenicity studies. The updated platform integrates multiple experimental approaches with customizable strategies, enabling more accurate identification of antibody ...
Protheragen, a dedicated preclinical research service provider specializing in rare diseases, announces its comprehensive diagnostic development services aimed at empowering researchers in the realm of rare disease research and drug development. These diagnostic services are designed to support the scientific community in identifying, understanding, and ultimately treating rare diseases that ...
Creative Biolabs Shines at the 2024 NIH Research Festival: Showcasing Antibody Solutions Creative Biolabs made a splash at the 2024 NIH Research Festival, held from Sept. 23–25, as they highlighted their groundbreaking work in antibody discovery and development. The festival, which featured scientific lectures, poster presentations, and workshops, was a vibrant hub of knowledge exchange, ...
CD Formulation, a leader in biotechnological innovation, is advancing the field of targeted drug delivery with its customized metal-organic frameworks (MOFs) services. The company has introduced a state-of-the-art approach to enhance the precision and efficiency of delivering therapeutic antibodies directly to targeted sites, aiming to boost therapeutic efficacy while reducing unwanted side ...
Introduction We recently sat down with one of our valued customers, Dr Alexis Rossignol (Clean Cells), to discuss his experience with VIPS PRO, our cutting-edge technology designed to streamline and enhance the early stages of cell line development. This interview provides insight into Clean Cells’ quest to automate and increase single-cell seeding while having undisputable proof ...
CD ComputaBio, a reputable computational service provider in the field of biology, has proudly announced the launch of its Antibody De Novo Design technology, marking a pivotal moment in the field of drug discovery and development. This service harnesses the power of AI to engineer antibodies with unmatched precision, paving the way for targeted therapies, personalized medicine, and cutting-edge ...
Creative Enzymes, a prominent player in the biotechnology sector, proudly introduces an innovative line-up of exceptional extracts, tailored to meet a wide spectrum of application needs. From plant extracts and animal extracts to mushroom extracts and vegetable powders, etc., this new collection promises to redefine the utilization of natural ingredients across industries. In a dynamic world ...
BRYAN, Texas, Jan. 05, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,545,238, entitled “Machine Learning Method For Protein Modelling To Design Engineered Peptides,” which ...
Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of November at the Old ...
Although it can be argued that therapeutic antibody development relies on semi-random search-and-selection methods, such as phage display and biopanning, there is an increasingly important role played by structure-based design. ...
PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022 DAEJEON, South Korea, October 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company’s first immuno-oncology ...
Upon closing of their proposed Business Combination, Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., and is expected to be listed on NASDAQ under the symbol, “OCEA”. Providence, RI and New York, NY, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Ocean Biomedical and Aesther Healthcare Acquisition Corp. ...
PharmAbcine Signs MoU with FutureChem to Explore Possibilities of Developing Novel Radiopharmaceuticals PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that it signed an MoU (Memorandum of Understanding) with FutureChem Co., Ltd. (“FutureChem”) (KOSDAQ: 220100ks), a leading ...
BOC Sciences has placed great emphasis on microbial fermentation techniques for years. Its comprehensive fermentation CDMO services and small microbial molecules have delivered tremendous value to the pharmaceutical industry. And the future looks even better. Pharmaceutical enterprises have been confronted with numerous challenges, such as rising cost pressures and uncertainty in the upstream ...
THOUSAND OAKS, Calif., May 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower people to take action when it comes to psoriatic arthritis. As a singer, dancer and entertainer, Bass understands the importance of staying in tune with your body. Through the campaign, he has created ...
Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces the enrolment and treatment of the first patient in its multicentre SCIB1 Phase 2 clinical trial at the Churchill Hospital, Oxford University Hospitals Trust, UK. The Phase 2 study is designed to assess whether the addition of SCIB1 to pembrolizumab ...
ByScancell
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Philipp Probst, Ph.D., Associate Director of ADC Research at Araris, will present data on the company’s linker technology at the 12th Annual World ADC London Conference. The poster presentation, titled, "Broadening the therapeutic index of antibody-drug conjugates ...
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Philipp Probst, Ph.D., Associate Director of ADC Research at Araris, will present data on the company’s linker technology at the 12th Annual World ADC London Conference. The poster presentation, titled, "Broadening the therapeutic index of antibody-drug conjugates ...
PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for ...